Business
Eupraxia Pharmaceuticals Announces Appointment of Dr. Mark Kowalski as Chief Medical Officer
Eupraxia Pharmaceuticals Announces Appointment of Dr. Mark Kowalski as Chief Medical Officer ...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Announces Appointment of Dr. Mark Kowalski as Chief Medical Officer\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n VICTORIA, BC\n \n \n ,\n \n \n May 18, 2023\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has appointed\n \n Mark Kowalski\n \n , MD, PhD, as the Company's Chief Medical Officer (\"CMO\"), effective\n \n May 18, 2023\n \n .\n \n \n Dr.\n \n James Helliwell\n \n , CEO of Eupraxia said, \"Mark is an accomplished clinical leader with more than two decades of experience in global clinical development and regulatory strategy. As we approach our Phase 2 readout with EP-104IAR in osteoarthritis, expected in the second quarter of this year, together with the broadening of our pipeline with additional drug candidates, the need for an experienced CMO has become compelling. We are pleased to attract a candidate of Dr. Kowalski's calibre to this critical role and welcome Mark to the team.\"\n \n \n \"I am excited about the prospects of Eupraxia's lead candidate EP-104IAR in osteoarthritis and the broader utility of the underlying technology platform,\" said Dr. Kowalski. \"This is an exciting time to be joining the Company and I look forward to working with the team as we advance this technology in the clinic and potentially through to commercialization.\"\n \n \n \n Dr. Mark Kowalski Background\n \n \n \n Dr. Kowalski has more than 20 years of experience in the pharmaceutical and biotech industry. He is a clinical leader, developing regulatory strategy and global clinical development plans for a variety of product types including small molecules, biologics (monoclonals, immunoconjugates, siRNAs) and vaccines, while working in a range of indications, including oncology, infectious diseases, urology, analgesia, allergy, rheumatology and metabolic disorders.\n \n \n He brings to Eupraxia experience with clinical s...